*All times are in EST


Fri 28

MPNs Day agenda TBC


Sat 29

8:00AM -8:10AM

Introduction & meeting objectives and keynote talks – Amer Zeidan

8:10AM -9:20AM

Session 1: CHIP/CCUS – Michael Savona and Uma Borate     

  • The SEARCH CONSORTIUM: Looking for Answers in CHIP And CCUS; Zhuoer Xie
  • Clonal hematopoiesis and transplantation outcomes; Coleman Lindsley
  • Should CCUS be considered as lower risk MDS?; Uma Borate
  • Putting it all together; Michael Savona

Panel discussion

9:20AM -9:40AM

Keynote talk:

Leveraging the icMDS combined database to answer timely and important questions on classification and risk stratification in MDS: Matteo Della Porta

9:40AM -10:00AM


10:00AM -11:00AM

Session 2: CMML – Michael Savona and Valeria Santini                   

  • RASopathies; Key Features of Ras-Family Mutated CMML, and Treatment Options; Mrinal Patnaik
  • Approaches from the MDS/MPN IWG: ABNL MARRO, and beyond; Daniel Wiseman
  • Elucidating the role of HMAs in CMML-A standard of care or not? Lisa Pleyer
  • The Special Case of MDS/MPN-RS-T; Valeria Santini

Panel discussion

11:00AM -12:00PM

Session 3: Epigenetics and Splicing

Chairs: Valeria Santini and Elizabeth Griffiths                                    

  • Oral hypomethylating agents in MDS-what is next?; Elizabeth Griffiths
  • Updates in therapeutic combinations of epigenetic agents in MDS/AML; Aristoteles Giagounidis
  • Pathophysiology and targeting of splicing factor mutant MDS and CMML; Jacqueline Boultwood
  • Overview of the NIH Program for MDS; Alain Mina

Panel discussion

12:00PM -1:00PM


1:00PM -2:30PM

Session 4: Inflammation and Immune interventions

Chairs: Andrew Wei and Rena Buckstein                                                                                                  

  • Targeting inflammation & dysregulated innate immunity in MDS; Shahram Kordasti
  • Updates in Vexas Syndrome; Carmelo Gurnari
  • IRAK inhibitors in MDS and AML; Uwe Platzbecker
  • How can we optimize transplant outcomes for MDS?; Charles Craddock
  • What we have learn from AML immune contexture that can be relevant to MDS?;
    Leonido Luznik

Panel discussion

2:30PM -3:50PM

Session 5: Classification and risk stratification Updates

Chairs: Rena Buckstein and Maria Teresa Voso

  • Roadmap for harmonization of classifications; Somedeb Ball
  • Molecular data integration in prognostic tools; Elli Papaemmanuil
  • Prognosis assessment in resource-limited countries; Maria Teresa Voso
  • Predicting relapse risk in MDS post-transplant: Ready for primetime? Christopher Hourigan
  • The Role of Classification versus Prognostication in MDS Patients; Robert Hasserjian

Panel discussion

3:50PM -4:10PM


4:10PM -5:50PM

Session 6: Response assessment & regulatory considerations
Chairs:  Amer Zeidan & Kelly Norsworthy

Keynote talk: Proceedings from FDA/NCI workshop on drug development in MDS; Kelly Norsworthy

Panel discussion

  • How can we measure disease modification in LR-MDS; Rami Komrokji
  • Are molecular responses ready for prime time use in MDS? Katharina Götze
  • IWG response criteria evolution for higher risk MDS; Amer Zeidan

Panel discussion

5:50PM -6:00PM

Day 1 Wrap-up


Sun 30

9:00AM -9:50AM

Session 7: TP53 aberrations and Secondary AML
Chairs: Valeria Santini & Andrew Wei 

  • How to use TP53 status for clinical decisions in MDS?; Coleman Lindsley
  • Therapies for secondary AML; Thomas Cluzeau
  • Targeting the CD47-SIRPa axis in MDS/AML; David Sallman
  • TP53 focused initiative in MDS MyeloMatch; Maximilian Stahl
  • Putting it together: current and future perspectives in TP53 mutated AML; Andrew Wei

Panel discussion

9:50AM -11:00AM

Session 8: Advances in LR-MDS therapies
Chairs: Uwe Platzbecker & Olatoyosi Odenike   

  • Telomerase inhibition; Uwe Platzbecker
  • TGF pathway modulation; Lionel Ades
  • Should lenalidomide become SOC in del5q LR-MDS before needing transfusions? María-Díez Campelo
  • myeloMATCH efforts to move clinical trial development ahead in MDS; Olatoyosi Odenike
  • Putting it together-how do I manage LR-MDS in 2023; Valeria Santini

Panel discussion

11:00AM -11:20AM


11:20AM -12:30PM

Session 9: Updates in HR-MDS therapies
Chairs: Andrew Wei and Amer Zeidan

  • IDH inhibitors- mono or combination therapy in MDS?;  Marie Sebert
  • RARA agonists- Updates in use of RARA agonists in MDS?; Amy DeZern
  • Updates on TIM3 targeting in MDS and AML?; Amer Zeidan
  • Putting all together; New directions in management of HR-MDS Andrew Wei

Panel discussion

12:30PM -1:20PM

Session 10: Big data and quality of life measures
Chairs: Rena Buckstein and Mikkael Sekeres

  • Should we include frailty and geriatric assessment in prognostic tools; Rena Buckstein
  • The HARMONY Alliance: A Big Data platform for patients with hematologic malignancies; Guillermo Sanz
  • Artificial Intelligence for MDS prognostication; Adrián Mosquera Orgueira
  • QOL in MDS: what are its predictors and what does it predict?; Fabio Efficace
  • How should we integrate quality of life as an endpoint in trials; Mikkael Sekeres

Panel discussion

1:20PM -1:30PM

End of meeting summary